ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Galectin Therapeutics Inc

Galectin Therapeutics Inc (GALT)

1.16
-0.01
(-0.85%)
Cerrado 05 Enero 3:00PM
1.175
0.015
(1.29%)
Fuera de horario: 6:59PM

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

GALT Noticias

Solo noticias oficiales
Rendering Error

GALT Finanzas

Finanzas
Rendering Error

GALT Discussion

Ver más
sunspotter sunspotter 4 horas hace
I rather think you missed the point. It’s not that higher doses of GALT’s drug are toxic, it’s that they are ineffective.

Given the purported mechanism, that almost certainly means lower doses are too, and that the implication that the lower dose worked is merely an artefact.

I rather like it here and have posted on this MB for over a decade. I’ll hang around whether you like it or not.
👍️0
Ecomike Ecomike 9 horas hace
Insider director buy a day ago, above the price I paid days ago.

I like it, I love it, I want some more of it.

Shorts have no shares left to borrow and the cost to borrow is 98%
Holy shit Sherlock, never seen that before. Ever heard of a bear trap?
The guy funding GALT is no Dummy, and experienced and super rich $$$$$$.

⌛️⌛️⌛️ ⌛️ ⌛️

https://ih.advfn.com/stock-market/NASDAQ/galectin-therapeutics-GALT/stock-news/95177233/form-4-statement-of-changes-in-beneficial-owners
👍️0
Ecomike Ecomike 9 horas hace
Indeed:

Superior article and well written by Zerohedge. It not only explains and identifies the efficacies, but exposes the real world greed factors that are slowing down progress by the research that should be getting the attention and funding. So looking forward to the new bosses at our health agencies that seem to be raring to go in cleaning up the corruption within the FDA etc and Big Pharma. Thanks for posting this article.
👍️0
Ecomike Ecomike 10 horas hace
#DHMO is deadly in higher doses as well, but life can not exist with out it.

https://www.DHMO.org

There is no logic or basis in that BS you posted. Shorts are drowning with no shares left to borrow. They dug their own grave.

So move along little short doggie.
👍️0
Monroe1 Monroe1 3 días hace
Superior article and well writtien by Zerohedge. It not only explains and identifies the efficacies but exposes the real world greed factors that are slowing down progress by the research that should be getting the attention and funding. So looking forward to the new bosses at our health agencies that seem to be raring to go in cleaning up the corruption within the FDA etc and Big Pharma. Thanks for posting this article.
👍️ 1 💥 1 💯 1 😍 1 😎 1
govprs govprs 2 semanas hace
I sold everything.  Big loss but wasn't going to wait this out further.  It's a shame mgmt was so confident back in April.  Baby biotechs simply haven't been good to me.  
👍️0
sunspotter sunspotter 2 semanas hace
When the lower dose appears to work better than the higher dose, the straw-grasping begins.

Seasoned pharma aficionados know that in reality it was a data artefact and that means the drug doesn’t work, which is why neither dose was better than placebo.
👍️0
sunspotter sunspotter 2 semanas hace
Quelle surprise.
👍️0
tw0122 tw0122 2 semanas hace
GALT bad results 
👍️0
govprs govprs 3 semanas hace
Ok I wasn't sure if your referring to bixt Galt or both.  Mike sheikh is part of bixt.  Not Galt as far as I know.  Are they both scams or just Galt? 
👍️0
sunspotter sunspotter 3 semanas hace
Nope. I never short stocks. Too risky.

I'm in the camp that thinks GALT/PRWP has always been long on lies and short on real drug candidates.
👍️0
govprs govprs 3 semanas hace
So your in the short camp?  
💯 1
sunspotter sunspotter 3 semanas hace
Adam F is right about GALT, just like The Boston Globe was right about PRWP, GALT’s previous incarnation.

https://www.thestreet.com/investing/stocks/biotech-stock-mailbag-aspenbio-10741455
😎 1 🤢 1 🤣 1 ⌛️ 1
govprs govprs 3 semanas hace
https://www.insiderfinancial.com/post/short-mafia-attacking-galectin-therapeutics-nasdaq-galt-ahead-of-planned-year-end-readout
👍️ 1
govprs govprs 2 meses hace
https://www.insiderfinancial.com/post/galectin-therapeutics-nasdaq-galt-disrupting-mercks-cancer-dominance
👍 1
Retire43 Retire43 3 meses hace
GALT MENTIONED IN THIS ARTICLE

https://www.zerohedge.com/news/2024-10-15/what-merck-doesnt-want-you-know-about-keytruda
👍️ 1
Retire43 Retire43 3 meses hace
Please watch this and comment your opinion

👍️ 1
sunspotter sunspotter 4 meses hace
Any company that has Ben Carson on its BoD is doomed to failure.
👍️0
govprs govprs 4 meses hace
Good things about to happen here
👍️0
Retire43 Retire43 6 meses hace
https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html
👍️0
Retire43 Retire43 7 meses hace
https://medicaldialogues.in/medicine/news/galectin-3-promising-biomarker-for-predicting-long-covid-among-patients-of-covid-19-study-129158
👍️0
Retire43 Retire43 8 meses hace
Todays emerging growth conference
CEO DAVID PLATT $BIXT
BioxyTran.

https://emerginggrowth.com/emerging-growth-conference-70/

👍️0
Retire43 Retire43 8 meses hace
https://www.nasdaq.com/press-release/6-stocks-positioned-to-soar-as-investors-focus-on-mash-2024-04-22
👍️0
Monksdream Monksdream 9 meses hace
Reached a peak.
👍️0
vein vein 9 meses hace
Letting some air out today !!
👍️0
vein vein 9 meses hace
But I had 20,000 !!!
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
AND AT 2.45...YA GOT ME BEAT BIG TIME!
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
ONLY...LOL...I ONLY HAVE A 1000..NICE WORK CHAMP!!
👍️0
vein vein 9 meses hace
Man , I only bought 5000 shares at 1.20 . Happy but I should have loaded the boat a bit more.
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
GALT...THESE BIO BEAST OF THE BIO MARKET
👍️0
Retire43 Retire43 9 meses hace
https://www.insiderfinancial.com/post/galectin-therapeutics-galt-a-discount-opportunity-moving-on-analysts-upgrade
👍️0
Retire43 Retire43 9 meses hace
Hey look at this;
GALT shareholders!
If you want an alternative to or additionally own a Galectin drug by the creator of Galectin antagonist, Dr Platt the father of the new science glycovirlogy

Viruses
Cancer
And hypoxia drug! BXT 25

https://www.insiderfinancial.com/post/galectin-therapeutics-galt-a-discount-opportunity-moving-on-analysts-upgrade
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
GALT..THE BIO BEAST THAT KEEPS BEASTING...
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
GALT the bio beast of the bio techs
👍️0
Monksdream Monksdream 9 meses hace
GALT new 52 hi
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
GALT BREAKING OUT
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
Play the chart not the story and sell before news
👍️0
vein vein 9 meses hace
What do we think this run is credited to ?? Our data readout isn’t until Q4??
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
GALT WEEKLY BREAK OUT HERE IS STRONG
👍️0
Monksdream Monksdream 9 meses hace
GALT new 52 hi
👍️0
TrendTrade2016 TrendTrade2016 9 meses hace
GALT BIO BEAST!!!
👍️0
vein vein 9 meses hace
Just trying to justify the run here. I’m happy of course , my entry was 1.20
👍️0
Monksdream Monksdream 9 meses hace
So sell short
👍️0
vein vein 9 meses hace
With no news , trial results not for a long time
👍️0
Monksdream Monksdream 9 meses hace
GALT new 52 hi
👍️0
vein vein 9 meses hace
Hmmm could be
👍️0
Monksdream Monksdream 9 meses hace
Professional asset manager support
👍️0
vein vein 9 meses hace
Wonder why we have such positive movement here ???
👍️0
Monksdream Monksdream 9 meses hace
GALT under $3
👍️0
Glycobio Glycobio 1 año hace
In any case, setting aside the noise, the most important thing is that this is the only drug candidate in a late stage clinical trial which has the potential to address a fatal complication of NASH cirrhosis. The excess galectin-3 in the disease process increases fibrotic activity and portal hypertension. GALT's galectin-3 inhibitor, belapectin, is a large chain carbohydrate compound that has side chains that are similar to the natural galectin-3 ligand, and inhibits the excess galectin-3 produced by macrophages in the liver. Since the body can metabolize this carbohydrate compound without relying on the liver, it does not put extra strain on the liver, which is why they had good results recently from the 4th data safety monitoring board (unlike competitors who keep running into safety issues with their liver drugs). When this galectin-3 pathway disease process is kept in check, it stabilizes portal hypertension, with the goal of reducing the formation of esophageal varices that develop from excess portal hypertension. Many cirrhosis patients die from bleeding varices. GALT could potentially offer a breakthrough treatment for the subgroup of patients who have not developed varices yet, by repeating prior phase 2 results in this phase 2/3 adaptive trial. As an investment it is very interesting because the stock price is so low right now compared to the risk/reward which I think is pretty good. If successful with the next readout the market cap could jump to billions.

By the way I have zero connection with the company or anyone associated with the company. I have an interest in glycobiology research which is why I study these topics in depth. I randomly came across this inverstorshub board and noticed a lot of misinformation or misguided info here so I figured I'd pitch in with some knowledge.
👍️0

Su Consulta Reciente

Delayed Upgrade Clock